Navigation Links
Ceregene Announces Two Key Additions to Leadership Team
Date:4/23/2008

SAN DIEGO, April 23 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today announced that it has added two key people to its management team. Maurice Mezzino has been hired to the position of vice president, chief business officer, and Andrea Loewen-Rodriguez joins the company as senior director, regulatory affairs. These positions have been created to support development and commercial activities as Ceregene transitions to a later stage biotechnology company with two product candidates in clinical trials -- CERE-110 for Alzheimer's disease and CERE-120 for Parkinson's disease.

"We are excited to add two such experienced professionals to our leadership team during a time when we are advancing our product candidates into late-stage clinical development, with CERE-120 for Parkinson's disease potentially entering Phase 3 clinical trials next year," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer. "Maurice will be a key contributor toward our business and partnering strategies having structured and completed multiple deals during his career, and Andrea will play an important role in liaising with the FDA and European regulators in our efforts to move our therapies through the approval process."

Maurice Mezzino, a business development executive with more than 20 years of biopharmaceutical industry experience, joins us from Biogen Idec, where he has been since 2000, serving most recently as vice president, business development, responsible for managing the west coast business development team. Among his accomplishments, Mr. Mezzino spearheaded an oncology strategic alliance between IDEC and Biogen in 2003, which was a precursor to the merger between the companies later that year; and in 2006 he led the acquisition of Conforma Therapeutics. Prior to Biogen Idec, Mr. Mezzino held a variety of positions in clinical development, business planning, strategic marketing and business development at Bristol-Myers Squibb Company, Schering-Plough Corporation, Hoechst-Roussel Pharmaceuticals and Ayerst Laboratories. Maurice received a BA degree in environmental biology from Rutgers University, an MS degree in microbiology from Louisiana State University and an MBA in finance from Fairleigh Dickinson University. He is also a Chartered Financial Analyst (CFA).

Andrea Loewen-Rodriguez, a regulatory affairs professional with more than 18 years of biopharmaceutical industry experience, joins us from the regulatory affairs division at Biogen Idec, where she has been since 2000. Her responsibilities included developing and implementing global regulatory strategies and submissions for multiple products in clinical development. Prior to Biogen Idec, Ms. Loewen-Rodriguez held various positions with Nexell Therapeutics and Baxter Healthcare Corp. Andrea holds a Regulatory Affairs Certification and received her BA degree in biology from Gustavus Adolphus College.

About Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which has completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE) as well as Hamilton BioVentures and California Technology Partners.


'/>"/>
SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
2. Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call
3. Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2008 Financial Results
4. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
5. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
6. BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock
7. UltraTape Announces Sample Kits Available for Purchase Through Website
8. IMPAC Medical Systems Announces 2008 Laboratory Professionals of the Year
9. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
10. Fufeng Announces 2007 Annual Results
11. Pharmacyclics Announces It Received Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):